Display options
Cite
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res. 2010;2:53-9doi: 10.2147/cmar.s5009.
Lansigan, F., Stearns, D. M., & Foss, F. (2010). Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer management and research, 253-9. https://doi.org/10.2147/cmar.s5009
Lansigan, Frederick, et al. "Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma." Cancer management and research vol. 2 (2010): 53-9. doi: https://doi.org/10.2147/cmar.s5009
Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag Res. 2010 Feb 05;2:53-9. doi: 10.2147/cmar.s5009. PMID: 21188096; PMCID: PMC3004568.
Copy Download .nbib Format: NLM
Share it on

Cancer Manag Res. 2010 Feb 05;2:53-9. doi: 10.2147/cmar.s5009.

Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Cancer management and research

Frederick Lansigan, Diane M Stearns, Francine Foss

Affiliations

  1. Hematology/Oncology, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA;

PMID: 21188096 PMCID: PMC3004568 DOI: 10.2147/cmar.s5009

Abstract

Denileukin diftitox (Ontak(®)) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human disease. This fusion protein toxin combines the IL2 protein with diphtheria toxin, and targets the CD25 subunit of the IL2 receptor, resulting in the unique delivery of a cytocidal agent to CD-25 bearing T-cells. Historically, immunotherapy targeting malignant T-cells including monoclonal antibodies has been largely ineffective as cytocidal agents compared to immunotherapy directed against B-cells such as rituximab. This review will summarize the development of denileukin diftitox, its proposed mechanism of action, the pivotal clinical trials that led to its FDA approval, the improvements in quality of life, and the common toxicities experienced during the treatment of patients with CTCL. CTCL is often a chronic progressive lymphoma requiring the sequential use of treatments such as retinoids, traditional chemotherapy, or biological response modifiers. The incorporation of the immunotoxin denileukin diftitox into the sequential or combinatorial treatment of CTCL will also be addressed.

Keywords: cutaneous T-cell lymphoma; denileukin diftitox; fusion protein toxin

References

  1. Protein Eng. 1987 Dec;1(6):493-8 - PubMed
  2. Blood. 1998 Jan 15;91(2):399-405 - PubMed
  3. J Invest Dermatol. 2006 Mar;126(3):575-83 - PubMed
  4. J Clin Oncol. 2001 Jan 15;19(2):376-88 - PubMed
  5. Blood. 2002 Aug 15;100(4):1399-403 - PubMed
  6. Cancer Chemother Pharmacol. 1990;26(6):409-14 - PubMed
  7. J Clin Endocrinol Metab. 2006 Jun;91(6):2205-8 - PubMed
  8. Arch Dermatol. 2007 Jul;143(7):854-9 - PubMed
  9. Hematol Oncol Clin North Am. 2008 Oct;22(5):979-96, x - PubMed
  10. Arch Dermatol. 2003 Jul;139(7):857-66 - PubMed
  11. Science. 1992 Jul 17;257(5068):379-82 - PubMed
  12. Hematol Oncol Clin North Am. 2003 Dec;17(6):1485-507 - PubMed
  13. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14 - PubMed
  14. Am J Hematol. 1998 May;58(1):87-90 - PubMed
  15. Clin Lymphoma. 2000 Nov;1 Suppl 1:S27-31 - PubMed
  16. Blood. 2005 Jul 15;106(2):454-7 - PubMed
  17. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1982-6 - PubMed
  18. Am J Hematol. 2008 Jul;83(7):593-5 - PubMed
  19. J Immunother. 2005 Nov-Dec;28(6):582-92 - PubMed
  20. J Am Acad Dermatol. 1998 Jul;39(1):63-73 - PubMed
  21. J Invest Dermatol. 2005 Dec;125(6):xvi-xvii - PubMed
  22. Nature. 1985 Dec 5-11;318(6045):467-70 - PubMed
  23. Dermatologica. 1987;175 Suppl 1:145-50 - PubMed
  24. J Immunol. 1984 Oct;133(4):1691-5 - PubMed
  25. Cancer Treat Rep. 1979 Apr;63(4):725-8 - PubMed
  26. Nature. 1984 Oct 18-24;311(5987):626-31 - PubMed
  27. Blood. 2005 Feb 15;105(4):1640-7 - PubMed
  28. J Clin Oncol. 1993 Mar;11(3):570-9 - PubMed
  29. J Am Acad Dermatol. 2002 Jan;46(1):95-106 - PubMed
  30. Ann Intern Med. 1988 Sep 1;109(5):372-82 - PubMed
  31. Clin Lymphoma. 2002 Mar;2(4):222-8 - PubMed
  32. Annu Rev Med. 2006;57:381-402 - PubMed
  33. Br J Ophthalmol. 2006 Aug;90(8):1070-1 - PubMed
  34. J Immunol. 1995 Aug 1;155(3):1151-64 - PubMed
  35. J Biol Chem. 1990 Jul 15;265(20):11885-9 - PubMed
  36. Blood. 1992 May 15;79(10):2547-54 - PubMed
  37. J Exp Med. 1988 Feb 1;167(2):612-22 - PubMed
  38. Leuk Res. 2002 Dec;26(12):1077-83 - PubMed
  39. Cancer Res. 2004 Aug 15;64(16):5825-9 - PubMed
  40. Br J Haematol. 2007 Aug;138(4):502-5 - PubMed
  41. Semin Oncol. 2006 Feb;33(1 Suppl 3):S11-6 - PubMed

Publication Types